Inhibidores de PARP Una realidad? dónde y cuando?
|
|
- Meagan Daniels
- 5 years ago
- Views:
Transcription
1 Inhibidores de PARP Una realidad? dónde y cuando? Alberto Ocana Hospital Universitario Albacete Centro Regional Investigaciones Biomédicas CIC-Salamanca
2 DNA repair mechanisms DNA is continually exposed to endogenous and exogenous sources of damage, DNA repair pathways is required to maintain genomic integrity Failure to repair DNA damage can result in a variety of genomic aberrations: point mutations, chromosomal translocations, and gain or loss of chromosomal segments or entire chromosomes. These genomic alterations produce changes in cell physiology that drive tumor initiation BRCA1/2 are central players in the homologous recombination (HR) repair pathway, and loss of BRCA1/2 or other genes in the HR pathway can confer an HR-deficient phenotype in breast, ovarian, prostate, and other tumor types
3 Double-strand breaks (DSBs): non-homologous end joining (NHEJ) microhomology-mediated end joining (MHEJ) homologous recombination (HR) (BRCA1/2 mutations) Redundancy Single strand break: base excision repair (BER) (PARP1 inhibitors), nucleotide excision repair (NER) mismatch repair.
4 Response to platinum compounds Somatic BRCA mut
5 PARP INHIBITORS IN BREAST CANCER OlympiAD (NCT ) FDA approves olaparib for germline BRCA-mutated metastatic breast cancer On January 12, 2018, the Food and Drug Administration granted regular approval to olaparib tablets (Lynparza, AstraZeneca Pharmaceuticals LP), a poly (ADP-ribose) polymerase (PARP) inhibitor, for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gbrcam), HER2-negative metastatic breast cancer.
6
7 Treatment design Randomly assigned, in a 2:1 ratio, to receive olaparib tab lets (300 mg twice daily) or standard therapy: capecitabine administered orally at a dose of 2500 mg per square meter of body-surface area daily (divided into two doses) for 14 days, repeated every 21 days; eribulin mesylate administered intravenously at a dose of 1.4 mg per square meter on day 1 and day 8, repeated every 21 days; or vinorelbine administered intravenously at a dose of 30 mg per square meter on day 1 and day 8, repeated every 21 days. Crossover to olaparib was not permitted in this trial. Randomization previous use of chemotherapy for metastatic disease (yes vs. no) hormone-receptor status (hormone- receptor positive vs. triple negative) previous use of platinum-based therapy (yes vs. no)
8 Inclusion Criteria HER2-negative metastatic breast cancer that was hormone-receptor positive or was triple negative. Patients had a confirmed deleterious or suspected deleterious germline BRCA mutation; central testing with BRACAnalysis (Myriad Genetics) Patients had received no more than two previous chemotherapy regimens for metastatic disease Patients with hormone-receptor positive breast cancer had received at least one endocrine therapy Previous neoadjuvant or adjuvant treatment with platinum was allowed if at least 12 months had elapsed since the last dose. Previous treatment with platinum for metastatic disease was allowed if there was no evidence that disease progression had occurred during treatment.
9 Results Median progression free survival olaparib compared with standard therapy (7.0 months vs. 4.2 months; HR 0.58; 95% CI, 0.43 to 0.80; P<0.001). The response rate was 59.9% in the olaparib group and 28.8% in the standard-therapy group. Grade 3 or higher adverse events was 36.6% in the olaparib group and 50.5% in the standard-therapy group Treatment discontinuation due to toxic effects was 4.9% and 7.7%, respectively.
10
11
12
13 Results summary Median progression-free survival was 2.8 months longer Less toxic Grade 3 or higher adverse events was 36.6% in the olaparib group and 50.5% in the standardtherapy group Treatment discontinuation due to toxic effects was 4.9% and 7.7%, respectively FDA also granted marketing authorization for the BRACAnalysis CDx test (Myriad Genetic Laboratories, Inc.)
14 Is the magnitude of benefit large enough?.how can activity be improved?...patients selection Is the magnitude of benefit large enough? TDM1 Pertuzumab+trastuzumab Everolimus Palbociclib Unmet disease
15 Approved HRD Biomarkers for PARP Inhibitor Use: Germline and somatic BRCA Mutations Under evaluation:
16 ONGOING COMBINATIONS
17
18
19
20 Immunomodulators
21
22 Take home message On January 12, 2018, FDA approves olaparib for germline BRCA-mutated metastatic breast cancer: PFS 2.8 months Limitations PARP inhibitors have not been compared head-to-head against platinum. In OlympiAD, prior platinum was allowed only if there was no PD on treatment as platinum was not allowed as one of the control groups. Long standing side effects? late toxic effects is especially important for adjuvant setting where olaparib is currently evaluated (OlympiA trial) (NCT )
23 Future options Selection of patients: biomarkers of HR repair, triple negative tumors, response to platinum Genetic instability more important than just presence of mutations at BRCA genes In combination with other agents: immunomodulators?
24 Thanks for your attention
Lynparza. Lynparza (olaparib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.52 Subject: Lynparza Page: 1 of 5 Last Review Date: March 16, 2018 Lynparza Description Lynparza (olaparib)
More informationPARP inhibitors for breast cancer
PARP inhibitors for breast cancer Mark Robson, MD Memorial Sloan Kettering Cancer Center Agenda Mechanism of action Clinical studies Resistance mechanisms Future directions Poly (ADP-ribose) Polymerases
More informationDieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy
More informationLynparza. Lynparza (olaparib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.52 Subject: Lynparza Page: 1 of 4 Last Review Date: September 15, 2017 Lynparza Description Lynparza
More informationLYNPARZA (olaparib) oral capsule and tablet
LYNPARZA (olaparib) oral capsule and tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Lynparza) Reference Number: CP.PHAR.360 Effective Date: 10.03.17 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this
More informationMyriad Genetics mychoice HRD Update 06/30/2016
Myriad Genetics mychoice HRD Update 06/30/2016 1 Forward Looking Statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events
More informationMedia Contact: Ron Rogers Investor Contact: Scott Gleason (801) (801)
News Release Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Receives FDA Approval of BRACAnalysis CDx as Companion
More informationCarrier Frequency. Breast Cancer and Treatment Options in Patients with BRCA1/2 mutations. Olivia Pagani On behalf of Bella Kaufman
Breast Cancer and Treatment Options in Patients with BRCA1/2 mutations Olivia Pagani On behalf of Bella Kaufman Carrier Frequency Prevalence of an altered disease gene in a given population 1 Background
More informationBreast Cancer and Treatment Options in Patients with BRCA1/2 mutations. Olivia Pagani On behalf of Bella Kaufman
Breast Cancer and Treatment Options in Patients with BRCA1/2 mutations Olivia Pagani On behalf of Bella Kaufman Carrier Frequency Prevalence of an altered disease gene in a given population Background
More informationPARP inibitori nel trattamento del carcinoma mammario metastatico: recenti successi e prospettive future.
PARP inibitori nel trattamento del carcinoma mammario metastatico: recenti successi e prospettive future. Dr.ssa Angela Toss Centro Oncologico Modenese Università di Modena e Reggio Emilia MECHANISMS OF
More informationExpert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer. Reference Slides
Expert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer Reference Slides Overview BRCA Mutations and Breast Cancer Patients with BRCA mutations have an estimated 55% to 65% cumulative
More informationVirtual Journal Club. Ovarian Cancer. Reference Slides. Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies
Virtual Journal Club Ovarian Cancer Reference Slides Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies Mansoor R. Mirza, MD Copenhagen University Hospital Rigshospitalet
More informationBrian T Burgess, DO, PhD, GYN Oncology Fellow Rachel W. Miller, MD, GYN Oncology
Brian T Burgess, DO, PhD, GYN Oncology Fellow Rachel W. Miller, MD, GYN Oncology Epithelial Ovarian Cancer - Standard Current Treatment: Surgery with De-bulking + Platinum-Taxane based Chemotherapy - No
More informationObjectives: Describe poly-adp-ribose polymerase (PARP) inhibitors mechanism of action.
1 2 3 Role of PARP Inhibitors in Metastatic Breast Cancer Catie Chatowsky, PharmD PGY1 Pharmacy Resident Disclosure: I have nothing to disclose. Objectives: Describe poly-adp-ribose polymerase (PARP) inhibitors
More informationFDA Companion Diagnostic Testing and Implications for Pharmacy and Medical Directors
FDA Companion Diagnostic Testing and Implications for Pharmacy and Medical Directors Diana Brixner, PhD, RPh, FAMCP Professor, University of Utah Health Sciences Executive Director, Pharmacotherapy Outcomes
More informationUpdate on PARP inhibitors
Professor of Medicine Harvard Medical School Boston MA Update on PARP inhibitors Ursula Matulonis, M.D. Chief, Division of Gynecologic Oncology Brock-Wilson Family Chair Dana-Farber Cancer Institute History
More informationOverview and future horizons of PARP inhibitors in BRCAassociated. Judith Balmaña
Overview and future horizons of PARP inhibitors in BRCAassociated breast cancer Judith Balmaña PARP inhibitors: Mechanism of action Clinical development: Monotherapy In combination with chemotherapy Ongoing
More informationTriple-Negative Breast Cancer
June 2017 Triple-Negative Breast Cancer Amir Sonnenblick, MD, PhD Sharett institute of oncology Hadassah-Hebrew university medical center, Jerusalem, Israel This presentation is the intellectual property
More informationPARP Inhibitors: Patients Selection. Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016
PARP Inhibitors: Patients Selection Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016 OVARIAN CANCER (OC): MULTIPLES DISEASES Different types with different behaviour
More informationUpdate on PARP inhibitors: opportunities and challenges in cancer therapy
Update on PARP inhibitors: opportunities and challenges in cancer therapy Vanda Salutari Unità di Ginecologia Oncologica Fondazione Policlinico Universitario A. Gemelli vanda.salutari@policlinicogemelli.it
More informationAVANCES EN METODOLOGÍA DE LA INVESTIGACIÓN. Alberto Ocaña Hospital Universitario de Albacete
AVANCES EN METODOLOGÍA DE LA INVESTIGACIÓN Alberto Ocaña Hospital Universitario de Albacete Endpoints PFS as an endpoint Surrogate endpoints PCR-FDA accelerated approval Factors afecting PFS: censoring
More informationUpdates in Cancer Genetics & Genomics
Updates in Cancer Genetics & Genomics Jennifer R. Klemp, PhD, MPH, MA Associate Professor of Medicine, Division of Clinical Oncology Director, Cancer Survivorship Co-Program Leader, Cancer Prevention and
More informationRecrui ng now. Could you help by joining this study?
Pancrea c cancer POLO study Recrui ng now AstraZeneca is looking for people with BRCA-mutated metasta c pancrea c cancer to join POLO, a clinical study to help scien sts find be er treatments for this disease
More information2/21/2016. Cancer Precision Medicine: A Primer. Ovarian Cancer Statistics and Standard of Care in 2015 OUTLINE. Background
Cancer Precision Medicine: A Primer Rebecca C. Arend, MD Division of Gyn Oncology OUTLINE Background Where we are Where we have been Where we are going Targeted Therapy in Ovarian Cancer How to Individualized
More informationInherited Cancer Syndromes and the DNA Damage Response
Inherited Cancer Syndromes and the DNA Damage Response Inherited Breast Cancer and DNA Double- Strand Break Repair Michal Goldberg Department of GeneGcs The Hebrew University Cancer Hub, March 2014 Hallmarks
More informationLYNPARZA RECEIVES ADDITIONAL AND BROAD APPROVAL IN THE US FOR OVARIAN CANCER
This announcement contains inside information 18 August 2017 07:00 BST LYNPARZA RECEIVES ADDITIONAL AND BROAD APPROVAL IN THE US FOR OVARIAN CANCER Lynparza's new tablet formulation approved as maintenance
More informationBRACAnalysis CDx Technical Information
Myriad Genetics Laboratories, Inc. 320 Wakara Way, Salt Lake City, UT 84108 Phone: 1-800-469-7423 www.myriad.com NOTE: Test results should be communicated to the patient in a setting that includes appropriate
More informationEvaluation of BRCA1/2 and homologous recombination defects in ovarian cancer and impact on clinical outcomes
Evaluation of BRCA1/2 and homologous recombination defects in ovarian cancer and impact on clinical outcomes Melinda S. Yates, PhD Department of Gynecologic Oncology & Reproductive Medicine University
More informationFeasibility of Clinical Trial Implementation Genetically Eligible Prostate Cancer Patients Oliver Sartor, MD Cathryn E, Garvey, MS December 3, 2015
Feasibility of Clinical Trial Implementation Genetically Eligible Prostate Cancer Patients Oliver Sartor, MD Cathryn E, Garvey, MS December 3, 2015 Study Name Feasibility of Patient Population for proposed
More informationOptimizing DNA Damage Response- Targeting Therapies: Focus on Genetic Testing and Counseling
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of May 2017. The content and views presented in this educational activity are those of the
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(adp-ribose)
More informationInhibidores de PARP en cáncer de ovario
Inhibidores de PARP en cáncer de ovario Ma Pilar Barretina Ginesta Servicio Oncología Médica Hospital Universitari Dr. J. Trueta Institut Català d Oncologia Coordinación científica: Dr. Fernando Rivera
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Olaparib (Lynparza) for Ovarian Cancer - Resubmission September 20, 2017
pan-canadian Oncology Drug Review Final Clinical Guidance Report Olaparib (Lynparza) for Ovarian Cancer - Resubmission September 20, 2017 DISCLAIMER Not a Substitute for Professional Advice This report
More informationMedicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático
Medicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático Dra. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau. Barcelona Introduction Ovarian cancer is the fifth
More information"BRCAness," PARP and the Triple-Negative Phenotype
"BRCAness," PARP and the Triple-Negative Phenotype Prof Alan Ashworth, FRS Disclosures for Professor Alan Ashworth, FRS Consulting Agreements GlaxoSmithKline, Pfizer Inc Patent AstraZeneca Pharmaceuticals
More informationPrecision Genetic Testing in Cancer Treatment and Prognosis
Precision Genetic Testing in Cancer Treatment and Prognosis Deborah Cragun, PhD, MS, CGC Genetic Counseling Graduate Program Director University of South Florida Case #1 Diana is a 47 year old cancer patient
More information2015 EUROPEAN CANCER CONGRESS
2015 EUROPEAN CANCER CONGRESS 25-29 September 2015 Vienna, Austria SUMMARY The European Cancer Congress (ECC 2015) combined the 40th European Society for Medical Oncology (ESMO) congress with the 18th
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More informationUtilizing Clinical Pathways for Remission Maintenance in Ovarian Cancer
Utilizing Clinical Pathways for Remission Maintenance in Ovarian Cancer This educational activity is supported by educational grants from AbbVie, and TESARO, Inc. Faculty Robert P. Edwards MD Professor
More informationOlaparib for the treatment of breast cancer
Expert Review of Anticancer Therapy ISSN: 1473-7140 (Print) 1744-8328 (Online) Journal homepage: http://www.tandfonline.com/loi/iery20 Olaparib for the treatment of breast cancer Gaia Griguolo, Maria Vittoria
More informationChemotherapy With or Without Targeted Drugs* in Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Chemotherapy With or Without Targeted Drugs* in Metastatic Breast Cancer * Substances without published evidence based on at
More informationASCO 2018 investor event; breakout 2: Lynparza lifecycle; MRK collaboration
ASCO 208 investor event; breakout 2: Lynparza lifecycle; MRK collaboration Hyatt Conference Columbus208 Klaus Edvardsen, Senior Vice President, Head of Oncology, Global Medicines Development 04 June 208
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More informationSeptember 2017 A LOOK AT PARP INHIBITORS FOR OVARIAN CANCER. Drugs Under Review. ICER Evidence Ratings. Other Benefits. Value-Based Price Benchmarks
September 2017 Drugs Under Review ICER s report reviewed the clinical effectiveness and value of olaparib (Lynparza, AstraZeneca), rucaparib (Rubraca, Clovis Oncology), and niraparib (Zejula, Tesaro),as
More informationOncofocus. Patient Test Report
Oncofocus Patient Test Report Lead Clinical Scientist: Keeda Snelson Senior BMS: Tiffany Haddow Date: 04 May 2017 1 of 13 Surname Forename DOB Gender Histology # Primary site Tumour subtype Tissue Type
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationPROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute
PROSTATE CANCER HORMONE THERAPY AND BEYOND Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute Disclosures I am a Consultant for Bayer and Sanofi-Aventis
More informationFULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE
US-17452 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LYNPARZA safely and effectively. See full prescribing information for LYNPARZA. LYNPARZA
More informationImportanza del test genetico nel carcinoma mammario ed ovarico
Importanza del test genetico nel carcinoma mammario ed ovarico Lorena Incorvaia Azienda Ospedaliera Universitaria Policlinco «P.Giaccone» Palermo UOC Oncologia Medica Ovarian Cancer Breast Cancer The range
More informationTargeting DNA repair in BRCA 1/2 and Triple Negative Breast Cancer
Targeting DNA repair in BRCA 1/2 and Triple Negative Breast Cancer Andrew Tutt, MB ChB, PhD Consultant Oncologist/Director Breakthrough Breast Cancer Research Unit King s Health Partners Academic Health
More informationDr. Josep M. Del Campo Clínica Diagonal. Barcelona
Dr. Josep M. Del Campo Clínica Diagonal. Barcelona Nuevas Oportunidades en Cáncer de Ovario Cancer de Ovario: Es una enfermedad única? Cáncer de Ovario: Tratamiento actual Tratamiento inicial: sin cambios
More informationPARP Inhibitors for Ovarian Cancer: Effectiveness and Value
PARP Inhibitors for Ovarian Cancer: Effectiveness and Value Draft Voting Questions for September 14, 2017 Public Meeting These questions are intended for the deliberation of the Midwest CEPAC voting body
More informationOverview of peculiarities and therapeutic options for patients with breast cancer and a BRCA germline mutation
Overview of peculiarities and therapeutic options for patients with breast cancer and a BRCA germline mutation Dr Niklas Loman PhD MD Consultant oncologist Skåne University Hospital Lund, Suecia Prognosis
More informationRicombinazione omologa nel carcinoma ovarico: BRCA e oltre. F. Raspagliesi MD
Ricombinazione omologa nel carcinoma ovarico: BRCA e oltre F. Raspagliesi MD raspagliesi@istitutotumori.mi.it BRCA molecular signature in ovarian cancer In a pooled analysis of 26 observational studies
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationAuthor s response to reviews
Author s response to reviews Title: A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1 or -2 mutated Her2
More informationWhat is New in Genetic Testing. Steven D. Shapiro MS, DMD, MD
What is New in Genetic Testing Steven D. Shapiro MS, DMD, MD 18th Annual Primary Care Symposium Financial and Commercial Disclosure I have a no financial or commercial interest in my presentation. 2 Genetic
More informationCancers du Sein Métastatiques
Cancers du Sein Métastatiques Véronique Diéras Journée Laurence Leroyer Rennes 18 mai 2018 Plan ESME Inhibiteurs CDK 4/6 RH+ Inhibiteurs PARP Anticorps drogue-conjugués Perspectives 2018-2019 ESME Time
More informationJosé Baselga, MD, PhD
i n t e r v i e w José Baselga, MD, PhD Dr Baselga is Physician-in-Chief at Memorial Sloan-Kettering Cancer Center in New York, New York. Tracks 1-15 Track 1 Track 2 Track 3 Track 4 Track 5 Track 6 Track
More informationSummary... 2 TRANSLATIONAL RESEARCH Tumour gene expression used to direct clinical decision-making for patients with advanced cancers...
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 TRANSLATIONAL RESEARCH... 3 Tumour gene expression used to direct clinical decision-making for patients with advanced
More informationPfizer Presents Final Phase 2 Data on Investigational PARP Inhibitor Talazoparib in Patients with Germline BRCA-Positive Advanced Breast Cancer
For immediate release June 3, 2017 Media Contact: Sally Beatty (212) 733-6566 Investor Contact: Ryan Crowe (212) 733-8160 Pfizer Presents Final Phase 2 Data on Investigational PARP Inhibitor Talazoparib
More informationTechnology appraisal guidance Published: 27 January 2016 nice.org.uk/guidance/ta381
Olaparib for maintenance treatment of relapsed, platinum-sensitive, e, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum- based chemotherapy
More informationEx vivo functional assays for Homologous Recombination deficiency in breast cancer. Dik C. van Gent
Ex vivo functional assays for Homologous Recombination deficiency in breast cancer Dik C. van Gent Breast cancer types treatments ER/PR: anti-hormonal therapy HER2: Herceptin Triple negative (TNBC): no
More informationPractical Guidance and Strategies for PARP Inhibition. Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy
Practical Guidance and Strategies for PARP Inhibition Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy Clinical Data Maintenance therapy : BRCA-mutated or all
More informationTNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017
TNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017 The problem with TNBC 1. Generally more aggressive 2. ONLY chemotherapy 3. No other
More informationTechnology appraisal guidance Published: 4 July 2018 nice.org.uk/guidance/ta528
Niraparib for maintenance treatment of relapsed, platinum-sensitive e ovarian, fallopian tube and peritoneal cancer Technology appraisal guidance Published: 4 July 2018 nice.org.uk/guidance/ta528 NICE
More informationClovis Oncology Announces First Quarter 2017 Operating Results. May 3, :06 PM ET
Clovis Oncology Announces First Quarter 2017 Operating Results May 3, 2017 4:06 PM ET Strong Q1 launch quarter for Rubraca (rucaparib) in U.S. with $7M reported in net sales Clovis notified that ARIEL3
More informationA New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG
A New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG Arizona Oncology (US Oncology Network) Professor, Gynecologic Oncology University of Arizona and Creighton
More informationOLAPARIB MONOTHERAPY AS MAINTENANCE TREATMENT OF PATIENTS WITH PLATINUM-SENSITIVE RELAPSED GERMLINE BRCA MUTATED (gbrcam) OVARIAN CANCER
Drug Substance Olaparib (AZD2281) OLAPARIB MONOTHERAPY AS MAINTENANCE TREATMENT OF PATIENTS WITH PLATINUM-SENSITIVE RELAPSED GERMLINE BRCA MUTATED (gbrcam) OVARIAN CANCER SPONSOR BRIEFING DOCUMENT FDA
More informationPatient-Centric Science-Based Performance-Driven
Patient-Centric Science-Based Performance-Driven Cowen & Co. 38 th Annual Health Care Conference Michael Pehl, President and Chief Executive Officer March 12, 2018 Forward-Looking Statements This presentation,
More informationENFERMEDAD AVANZADA Qué hacemos con el triple negativo? Nuevas aproximaciones
ENFERMEDAD AVANZADA Qué hacemos con el triple negativo? Nuevas aproximaciones Javier Cortes, Hospital Universitario Ramon y Cajal, Madrid Vall d Hebron Institute of Oncology (VHIO), Barcelona Triple Negative
More informationPersonalised Medicine in Practice. Dr Ingrid Slade MBChB, PhD, MRCPCH, MFPH Dr Chris Spencer DPhil Dr Gabriele De Luca MD, DPhil
Personalised Medicine in Practice Dr Ingrid Slade MBChB, PhD, MRCPCH, MFPH Dr Chris Spencer DPhil Dr Gabriele De Luca MD, DPhil Personalised Medicine in Cancer Care Personalised Medicine in Cancer Care
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More informationMyriad Genetics Corporate Presentation 6/4/13
Myriad Genetics Corporate Presentation 6/4/13 Forward Looking Statement Some of the information presented here today may contain projections or other forward-looking statements regarding future events
More informationPresented at SGO - March 19, 2016
Homologous Recombination Deficiency (HRD) Score Shows Superior Association with Outcome Compared to its Individual Score Components (LOH, TAI, and LST Scores) in Platinum Treated Serous Ovarian Cancer
More informationConvegno Nazionale AIOM Giovani 2016: News in Oncology. Daniele Alesini. Istituto Nazionale dei Tumori Regina Elena
Convegno Nazionale AIOM Giovani 2016: News in Oncology Daniele Alesini Istituto Nazionale dei Tumori Regina Elena Something Old Something New Something Borrowed Something Blue DOCETAXEL: BACK AND FORTH
More informationTriple Negative Breast Cancer
GASCO 2016 San Antonio Breast Cancer Symposium Review Triple Negative Breast Cancer Amelia Zelnak, MD, MSc Atlanta Cancer Care Northside Hospital Cancer Institute Disclosures: consultant for Novartis,
More informationPoly ADP-Ribose Polymerase (PARP) Inhibitors for Ovarian Cancer: Effectiveness & Value. Evidence Report. August 30, 2017.
Poly ADP-Ribose Polymerase (PARP) Inhibitors for Ovarian Cancer: Effectiveness & Value Evidence Report August 30, 2017 Prepared for Institute for Clinical and Economic Review, 2017 ICER Staff/Consultants
More informationBreast Cancer Statistics
1 in 8 Breast Cancer Statistics Incidence Mortality Prevalence 2 Breast Cancer Incidence Breast Cancer Mortality Breast Cancer Prevalence ~$100,000 Female Breast Anatomy Breasts consist mainly of fatty
More informationHER2-Negative Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023
HER2-Negative Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023 HER2-Negative Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023 BioPortfolio has been marketing business and market
More informationTargeted therapy & Tumor molecular profile. Anton Tikhonov V Bioinformatics Summer School, 2017
Targeted therapy & Tumor molecular profile Anton Tikhonov V Bioinformatics Summer School, 2017 What exactly is targeted therapy? It has target It was rationally designed Its target was discovered before
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AWARD NUMBER: W81XWH-13-1-0484 TITLE: PRINCIPAL INVESTIGATOR: Elizabeth Swisher CONTRACTING ORGANIZATION: University of Washington REPORT DATE: 2014 TYPE OF REPORT: Annual Report PREPARED FOR: U.S. Army
More informationAmir Sonnenblick, Evandro de Azambuja, Hatem A. Azim Jr and Martine Piccart
An update on inhibitors moving to the adjuvant setting Amir Sonnenblick, Evandro de Azambuja, Hatem A. Azim Jr and Martine Piccart REVIEWS Abstract Inhibition of poly(adp-ribose) polymerase () enzymes
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 1Q17 January February
BRAND NAME Rubraca GENERIC NAME rucaparib MANUFACTURER Clovis Oncology, Inc. DATE OF APPROVAL December 19, 2016 PRODUCT LAUNCH DATE December 19, 2016 REVIEW TYPE Review type 1 (RT1): New Drug Review Full
More informationClinical Development of Rucaparib
Clinical Development of Rucaparib Rucaparib is an investigational product and not approved by any health authority. Conclusions about efficacy and safety cannot be made Development of HRD/LOH Signature
More informationTreatment options in patients with early breast cancer and BRCAmutations or family history of cancer
PHARMACOTHERAPY 239 Treatment options in patients with early breast cancer and BRCAmutations or family history of cancer M-D. t Kint de Roodenbeke, MD 1, L. Buisserer, MD, PhD 2, M. Piccart-Gebhart, MD,
More informationUpdate on Breast Cancer
Update on Breast Cancer William J. Gradishar, MD Professor of Medicine Robert H. Lurie Comprehensive Cancer Center Feinberg School of Medicine Northwestern University Overview PARP Inhibitors Neoadjuvant
More informationLearning Objectives. Page 1
Learning Objectives 1. Outline the role of the DNA damage response (DDR) pathway in tumor suppression and describe how mutations in DDR genes lead to tumor proliferation. 2. Explore recent advances in
More informationRUBRACA (rucaparib camsylate) oral tablet
RUBRACA (rucaparib camsylate) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationImmune therapy for women with recurrent ovarian cancer
Immune therapy for women with recurrent ovarian cancer Sarah Adams, MD Associate Professor, Division of Gynecologic Oncology University of New Mexico Comprehensive Cancer Center The problem: overall survival
More informationFILED: NEW YORK COUNTY CLERK 03/29/ :57 PM INDEX NO /2016 NYSCEF DOC. NO. 59 RECEIVED NYSCEF: 03/29/2017 EXHIBIT J
EXHIBIT J ASCO Clinical Data Update May 31, 2015 The Langham Hotel, Chicago Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations
More informationMultimedia Appendix 6 Educational Materials Table of Contents. Intervention Educational Materials Audio Script (version 1)
Multimedia Appendix 6 Educational Materials Table of Contents Intervention Educational Materials... 1 Audio Script (version 1)... 1 Text (version 1)... 5 Slides (version 1)... 17 Audio Script (version
More informationSU2C TOP SCIENCE ACCOMPLISHMENTS
SU2C TOP SCIENCE ACCOMPLISHMENTS INTRODUCTION Since our founding in 2008, Stand Up To Cancer has funded 87 team science projects, with budgets ranging from $250,000 for a short research project to over
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More informationClinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC)
Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Eric P Winer, MD Disclosures for Eric P Winer, MD No real or apparent conflicts of interest to disclose Key Topics: PARP and
More informationCONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
More informationProgress Update June 2017 Lay Summary Funding: $6,000,000 Grant Funded: July 2015 Dream Team Members Dream Team Leader:
SU2C -Ovarian Cancer Research Fund Alliance-National Ovarian Cancer Coalition Dream Team Translational Research Grant: DNA Repair Therapies for Ovarian Cancer AND SU2C Catalyst Merck-Supported Supplemental
More information